Systemic lupus erythematosus (SLE) is a devastating autoimmune disease that can result in
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …

The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …

Objective To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric
inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus …

Objective To update the 2012 EULAR/ERA–EDTA recommendations for the management of
lupus nephritis (LN). Methods Following the EULAR standardised operating procedures, a …

Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of
self-tolerance and formation of nuclear autoantigens and immune complexes resulting in …

Systemic lupus erythematosus (SLE), a worldwide autoimmune disease with high
heritability, shows differences in prevalence, severity and age of onset among different …

The treat-to-target (T2T) concept has improved outcomes for patients with diabetes,
hypertension and rheumatoid arthritis. This therapeutic strategy involves choosing a well …

Genome-wide association studies (GWAS) have provided insights into the genetic basis of
complex diseases. In the next step, integrative multi-omics approaches can characterize …

Therapeutic targeting of immune checkpoints has garnered significant attention in the area
of cancer immunotherapy, in which efforts have focused in particular on cytotoxic T …

The B cell activating factor (BAFF), or B lymphocyte stimulator (BLyS), is a B cell survival
factor which supports autoreactive B cells and prevents their deletion. BAFF expression is …